This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wikstrand, J. Articles by Leer, J. Search for Related Content PubMed PubMed Citation Articles by Wikstrand, J. Articles by Leer, J.

Hypertension, Vol 17, 579-588, Copyright © 1991 by American Heart Association

ARTICLES

Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study

J Wikstrand, I Warnold, J Tuomilehto, G Olsson, HJ Barber, K Eliasson, D Elmfeldt, B Jastrup, NB Karatzas and J Leer
Department of General Practice, University of Glasgow, Scotland.

The present study in hypertensive men (40-64 years old) with untreated diastolic blood pressure above 100 mm Hg was aimed at investigating whether metoprolol (n = 1,609) given as initial treatment would lower the risk for coronary events (sudden death and myocardial infarction) more effectively than thiazide diuretics (n = 1,625). A substantial part of this study was the metoprolol arm of the Heart Attack Primary Prevention in Hypertension (HAPPHY) study. The HAPPHY study was a pooling of the effect of different beta-blockers, mainly metoprolol and atenolol, in which no favorable effect in relative risk was observed for atenolol as compared with diuretics. In the present study, 255 patients suffered definite coronary events during follow-up; 25% of these events were fatal, 39% were acute myocardial infarctions, and 36% were silent myocardial infarctions. The risk for coronary events was significantly lower in patients on metoprolol than in patients on diuretics (111 versus 144 cases, p = 0.001, corresponding to 14.3 versus 18.8 cases/1,000 patient years and a relative risk of 0.76 at the end of the trial; 95% confidence interval 0.58-0.98). This difference in risk has potentially important implications for clinical practice because of the large number of hypertensive patients who are at increased risk for coronary events. Because a placebo group, for ethical reasons, could not be included, relative risk can only be expressed in relation to diuretics. There was no difference between the two treatment groups in baseline characteristics, blood pressure during follow-up, or stroke rates. Thus, the difference in risk for coronary events is probably mediated via mechanisms other than blood pressure control. However, present data might suggest that different beta- blockers may have different efficacy in preventing coronary events. The reasons for this possibility are as yet unknown.

This article has been cited by other articles:

				S. Bangalore, S. Sawhney, and F. H. Messerli Relation of Beta-Blocker-Induced Heart Rate Lowering and Cardioprotection in Hypertension J. Am. Coll. Cardiol., October 28, 2008; 52(18): 1482 - 1489. [Abstract] [Full Text] [PDF]

				S. Bangalore, D. Wild, S. Parkar, M. Kukin, and F. H. Messerli Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension: Insights From a Meta-Analysis J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1062 - 1072. [Abstract] [Full Text] [PDF]

				O. Onalan, B. E. Cumurcu, and L. Bekar Complete Atrioventricular Block Associated With Concomitant Use of Metoprolol and Paroxetine Mayo Clin. Proc., May 1, 2008; 83(5): 595 - 599. [Abstract] [Full Text] [PDF]

				R. J. Johnson, M. S. Segal, T. Srinivas, A. Ejaz, W. Mu, C. Roncal, L. G. Sanchez-Lozada, M. Gersch, B. Rodriguez-Iturbe, D.-H. Kang, et al. Essential Hypertension, Progressive Renal Disease, and Uric Acid: A Pathogenetic Link? J. Am. Soc. Nephrol., July 1, 2005; 16(7): 1909 - 1919. [Abstract] [Full Text] [PDF]

				A. K. Siddiqui, S. Ahmed, H. Delbeau, D. Conner, and J. Mattana Lack of Physician Concordance With Guidelines on the Perioperative Use of {beta}-Blockers Arch Intern Med, March 22, 2004; 164(6): 664 - 667. [Abstract] [Full Text] [PDF]

				O. Wiklund, J. Hulthe, J. Wikstrand, C. Schmidt, S.-O. Olofsson, and G. Bondjers Effect of Controlled Release/Extended Release Metoprolol on Carotid Intima-Media Thickness in Patients With Hypercholesterolemia: A 3-Year Randomized Study Stroke, February 1, 2002; 33(2): 572 - 577. [Abstract] [Full Text] [PDF]

				B. Hedblad, J. Wikstrand, L. Janzon, H. Wedel, and G. Berglund Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness : Main Results From the {beta}-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) Circulation, April 3, 2001; 103(13): 1721 - 1726. [Abstract] [Full Text] [PDF]

				B.R Brehm, S.C Wolf, D Bertsch, M Klaussner, S Wesselborg, S Schuler, and K Schulze-Osthoff Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells Cardiovasc Res, February 1, 2001; 49(2): 430 - 439. [Abstract] [Full Text] [PDF]

				J. M. Wright Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 2: {beta}-Blockers Can. Med. Assoc. J., July 1, 2000; 163(2): 188 - 192. [Abstract] [Full Text] [PDF]

				J. M. Wright, C.-H. Lee, and G. K. Chambers Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line drug? Can. Med. Assoc. J., July 1, 1999; 161(1): 25 - 32. [Abstract] [Full Text] [PDF]

				M. Suurkula, S. Agewall, B. Fagerberg, I. Wendelhag, and J. Wikstrand Multiple Risk Intervention in High-Risk Hypertensive Patients : A 3-Year Ultrasound Study of Intima-Media Thickness and Plaques in the Carotid Artery Arterioscler Thromb Vasc Biol, March 1, 1996; 16(3): 462 - 470. [Abstract] [Full Text]